New Enterprise Associates

Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.

Tune Therapeutics develops cell and gene therapies guided by epigenetic programming to treat devastating diseases. The company is building an epigenetic programming platform that enables new pathways for disease treatment by tapping into the epigenome to program biology without altering the DNA sequence. This approach aims to deliver paradigm-changing therapies by modulating gene expression through epigenetic mechanisms rather than editing the genome, expanding options for diseases where conventional treatments have limited efficacy. By integrating epigenetics and cell biology, the company seeks durable, precise interventions that can reprogram cellular states to restore function while minimizing genetic change. The emphasis is on research and development to advance candidates toward clinical use to address severe and unmet medical needs.

Ouroboros Medicines is a biotechnology company dedicated to immunology, focusing on treating chronic immune-mediated illnesses. It specializes in developing immune reset treatments, using a therapeutic platform that employs T cell engager antibodies to target and deplete specific pathogenic cells. This approach aims to provide extended remissions for patients, without the need for ongoing immunosuppression. The company's strength lies in its integration of scientific knowledge and proven track record in progressing cell-depleting treatments through clinical trials, supported by a robust pipeline.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

NeueHealth is a healthcare company dedicated to providing high-quality, coordinated care to aging and underserved populations. It operates through two segments: NeueCare, which manages risk in partnership with external payors, serving diverse patient populations; and NeueSolutions, offering technology, services, and clinical care solutions to empower providers.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

858 Therapeutics is a biotechnology company specializing in the discovery of small molecule therapeutics for novel targets in oncology and immunology. The company focuses on innovative approaches such as synthetic lethality, innate immunity, and RNA modulation, with its lead program being a PARG inhibitor currently in early clinical development.

PayZen is a healthcare fintech company that helps patients manage out-of-pocket medical expenses by offering flexible, transparent payment plans and non-recourse financing. The platform enables patients to pay bills over time while helping providers accelerate cash flow and reduce costly collections. It uses AI-powered risk assessment to tailor each plan to the individual patient, supporting affordable payments without upfront burden. Founded in 2019 in San Francisco by Ariel Rosenthal, Itzik Cohen, and Tobias Mezger, PayZen aims to reduce financial barriers to care while enabling providers to focus on delivering services.

Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

In-House Health is an AI-powered technical platform for modern nursing teams.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

NeueHealth is a healthcare company dedicated to providing high-quality, coordinated care to aging and underserved populations. It operates through two segments: NeueCare, which manages risk in partnership with external payors, serving diverse patient populations; and NeueSolutions, offering technology, services, and clinical care solutions to empower providers.

Nexo Therapeutics is a small molecule oncology company focused on discovering and developing innovative drugs for cancer patients who have limited therapeutic options. The company utilizes a unique platform that integrates covalent ligand discovery and chemical biology, allowing it to advance small-molecule therapies aimed at challenging and previously intractable cancer targets. By unlocking a pipeline of novel oncology treatments, Nexo Therapeutics seeks to provide medical professionals with new and effective options to improve patient outcomes in the fight against cancer.

Spyglass Pharma specializes in developing innovative treatments for chronic eye diseases using advanced technologies. The company aims to deliver multiple drugs to address additional ophthalmic indications.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Strive Health, LLC is a company focused on providing comprehensive solutions for chronic kidney disease. Founded in 2018 and based in Denver, Colorado, Strive Health operates dialysis centers and employs advanced predictive analytics to enhance patient care. The company offers a high-touch, technology-enabled clinical model that supports patients throughout their healthcare journey, from primary care engagement to dialysis treatment. By utilizing comparative and predictive data, Strive Health aims to identify at-risk patients and transform the management of kidney disease, promoting earlier intervention and increasing the adoption of home dialysis. This innovative approach not only improves patient outcomes but also seeks to reduce inpatient utilization, ultimately enhancing the overall experience for individuals dealing with chronic kidney conditions.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

FIRE1 is an Irish-based company specializing in the development of innovative therapeutic devices. Its flagship product is a remote monitoring system designed to enhance heart failure patients' lives by providing real-time data to healthcare providers, facilitating early detection and proactive interventions.

SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

Minerva Surgical Inc. is a medical technology company based in Redwood City, California, dedicated to women's healthcare. Founded in 2008, the company specializes in developing, manufacturing, and commercializing minimally invasive solutions for uterine health. Its flagship product, the Minerva Endometrial Ablation System, is designed to treat abnormal uterine bleeding, a common issue affecting many women. Minerva Surgical offers a comprehensive range of alternatives to hysterectomy, aiming to address the underlying causes of abnormal uterine bleeding while preserving the uterus. These solutions are applicable in various medical environments and seek to overcome the limitations of traditional treatment methods, providing women with effective and less invasive options for their healthcare needs.

Launchpad Therapeutics is an antibody-focused precision oncology company.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Elion operates a digital health software marketplace that connects healthcare providers with relevant vendors. Its platform facilitates informed decision-making through comprehensive vendor listings, product evaluations, and educational resources.

Moximed develops and provides the Atlas System, an implantable joint unloader designed to alleviate pain and preserve mobility in patients with medial compartment knee osteoarthritis. Its outpatient treatment option aims to improve quality of life for those not responsive to other therapies or candidates for knee replacement.

Founded in 2010, Everside Health provides direct primary care services, offering convenient on-site, near-site, and virtual care options for its members. The company's data-driven approach aligns incentives to benefit patients, physicians, and benefit providers while reducing the total cost of care.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Evernow offers comprehensive women's healthcare services focused on menopause. Their platform provides online access to specialized doctors, evidence-based information, treatments, and supportive communities, empowering women to manage hormonal changes and improve their overall health.

Nitra is a financial technology company focused on transforming the healthcare industry through innovative and efficient solutions. It provides a suite of machine learning-powered financial software that includes credit cards, loans, accounts, payments, and expense management tools specifically designed for medical professionals. Nitra's platform enables healthcare providers to streamline their financial operations, allowing them to balance patient care with practice management. Its offerings include a business card that rewards spending and fosters partnerships with various service providers, as well as user-friendly accounting and receipt reconciliation tools. Nitra is committed to equipping the healthcare sector with advanced technology and dedicated support, ensuring that financial management can be both effective and straightforward.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Founded in 2020 and headquartered in San Diego, California, Sorriso Pharmaceuticals is a biotechnology company dedicated to developing disease-modifying antibodies for treating inflammatory diseases such as Crohn's disease and ulcerative colitis. Its proprietary platform generates potent antibodies designed for oral delivery, aiming to maintain therapeutic activity throughout the intestinal system.

Belong Health collaborates with local health plans to deliver regionally tailored, personalized care to a growing community of individuals eligible for Medicare Advantage and dual-eligible special needs plans.

Simple psychology belongs to Beijing Zhujian Technology Co., Ltd. Simple psychology focuses on providing high-quality psychological services.

NeueHealth is a healthcare company dedicated to providing high-quality, coordinated care to aging and underserved populations. It operates through two segments: NeueCare, which manages risk in partnership with external payors, serving diverse patient populations; and NeueSolutions, offering technology, services, and clinical care solutions to empower providers.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Tune Therapeutics develops cell and gene therapies guided by epigenetic programming to treat devastating diseases. The company is building an epigenetic programming platform that enables new pathways for disease treatment by tapping into the epigenome to program biology without altering the DNA sequence. This approach aims to deliver paradigm-changing therapies by modulating gene expression through epigenetic mechanisms rather than editing the genome, expanding options for diseases where conventional treatments have limited efficacy. By integrating epigenetics and cell biology, the company seeks durable, precise interventions that can reprogram cellular states to restore function while minimizing genetic change. The emphasis is on research and development to advance candidates toward clinical use to address severe and unmet medical needs.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Recludix Pharma develops a platform for discovering potent and selective inhibitors of complex protein targets. The platform integrates custom-generated DNA-encoded libraries, massively parallel structure-activity relationship determination, and proprietary screening tools to ensure selectivity.

858 Therapeutics is a biotechnology company specializing in the discovery of small molecule therapeutics for novel targets in oncology and immunology. The company focuses on innovative approaches such as synthetic lethality, innate immunity, and RNA modulation, with its lead program being a PARG inhibitor currently in early clinical development.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Allay Therapeutics is pioneering ultra-sustained pain therapeutics to transform post-surgical pain management. Its proprietary platform combines non-opioid analgesics and biopolymers to create dissolvable therapeutics delivering pain relief within targeted sites over weeks, significantly longer than current treatments. The company's lead product candidate, ATX101, is in Phase 2 clinical trials for total knee replacement surgeries.

Woebot Health is a digital mental healthcare provider that offers a platform designed to deliver personalized support and guidance. Utilizing advanced artificial intelligence and natural language processing, Woebot Health incorporates clinically proven therapeutic techniques into its services. The centerpiece of its offering is Woebot, an engaging relational agent that facilitates continuous, empathic, and user-friendly interactions. This innovative approach allows individuals and organizations to access effective mental health support seamlessly, fitting into daily life and providing help whenever needed. Woebot Health aims to enhance mental well-being through scalable digital tools, making mental health resources more accessible to a broad audience.

Spiras Health operates a healthcare service that delivers specialized care to patients' homes for those managing complex chronic conditions. Their multidisciplinary clinical team offers services enhanced by telehealth, digital communications, and remote monitoring, aiming to improve patients' quality of life and reduce unnecessary hospitalizations.

Stablix Therapeutics is a biotechnology company specializing in Targeted Protein Stabilization (TPS). It develops heterobifunctional small molecules that recruit deubiquitinase enzymes to stabilize or enhance targeted proteins, focusing on treating rare diseases, cancer, and immunological disorders.

Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.

Collective Health provides a cloud-based health benefits platform that unifies medical, dental, vision, pharmacy, and related programs into a single administration experience, helping employers simplify benefits, guide employees in understanding and navigating care, and manage costs and outcomes. The platform offers integrated administration of all health plans through one portal, with live concierge support and digital tools to find and manage care, and connects employees with medical, pharmacy, dental, and vision providers. Headquartered in San Francisco with offices in Chicago and Lehi, it aims to reduce the administrative burden of delivering benefits while improving member experience and overall health outcomes.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Cleo Labs, Inc. is a family support platform that offers pregnancy consultancy and parenthood guidance services to working parents. The company provides a range of consultation services, including lactation support, birth preparation, child wellness, and sleep consulting, as well as career coaching and immediate post-birth assistance. Cleo's mobile application connects families with certified care practitioners, facilitating their journey from fertility through parenting children up to age five. By partnering with employers, Cleo aims to enhance workplace culture, improve employee retention, and foster diverse and inclusive environments. The company operates globally, serving clients in over 50 countries and has collaborated with notable organizations such as eBay and LinkedIn. Founded in 2016 and headquartered in San Francisco, Cleo was previously known as Instacare Group, Inc. before rebranding in 2018.

Strive Health, LLC is a company focused on providing comprehensive solutions for chronic kidney disease. Founded in 2018 and based in Denver, Colorado, Strive Health operates dialysis centers and employs advanced predictive analytics to enhance patient care. The company offers a high-touch, technology-enabled clinical model that supports patients throughout their healthcare journey, from primary care engagement to dialysis treatment. By utilizing comparative and predictive data, Strive Health aims to identify at-risk patients and transform the management of kidney disease, promoting earlier intervention and increasing the adoption of home dialysis. This innovative approach not only improves patient outcomes but also seeks to reduce inpatient utilization, ultimately enhancing the overall experience for individuals dealing with chronic kidney conditions.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat diseases like nonalcoholic steatohepatitis (NASH) and certain cancers. The company specializes in targeting dysfunctional metabolic pathways, with a particular expertise in fatty acid synthase (FASN) biology.

SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

Spyglass Ophthalmics, Inc. is a company based in Mission Viejo, California, specializing in the development of ophthalmic therapeutic devices. Founded in 2019, Spyglass focuses on creating innovative solutions to enhance vision and eye care for patients. The company's products target unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic diseases. By providing these devices, Spyglass aims to ensure that patients receive quality eye treatment at an affordable cost.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

NeueHealth is a healthcare company dedicated to providing high-quality, coordinated care to aging and underserved populations. It operates through two segments: NeueCare, which manages risk in partnership with external payors, serving diverse patient populations; and NeueSolutions, offering technology, services, and clinical care solutions to empower providers.

Eargo, Inc. is a consumer-focused medical device company specializing in the design and sale of hearing aids for individuals with hearing loss in the United States. Founded in 2010 and headquartered in San Jose, California, Eargo offers innovative, rechargeable hearing aids that can be controlled via smartphone, enhancing user convenience. The company provides online hearing screenings and virtual support, eliminating the need for in-person consultations. By adopting a direct-to-consumer model, Eargo aims to make hearing aids more accessible and reduce the social stigma often associated with them. Its user-centric approach addresses the common challenges of traditional hearing aid adoption, including cost and accessibility, thereby improving the quality of life for those with hearing difficulties.

CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Affinia Therapeutics develops adeno-associated virus (AAV) gene therapies for muscular and central nervous system diseases. The company uses an AAV vector design platform built on synthetic and systems biology, high-throughput screening, and tissue- and single-cell-resolution analyses to create vectors with improved properties. It leverages sequencing, artificial intelligence, and structural modeling to enable rational design of therapies. Headquartered in Waltham, Massachusetts, Affinia Therapeutics was founded in 2019 and targets diseases with significant unmet needs in muscle and CNS.

Pager, Inc. is a company that operates an on-demand service platform designed to connect patients with healthcare services in various settings including homes, offices, and hotels. The company offers a mobile application that facilitates access to urgent care for a range of conditions such as infections, respiratory issues, and allergies. In addition to its core services, Pager provides nurse chat, teleconsultation, screening, vaccination, and prescription delivery. The company's mission focuses on improving healthcare accessibility, lowering costs, and simplifying care navigation through a flexible platform that integrates artificial intelligence and service teams. Amidst its extensive offerings, Pager supports over 15 million individuals across the United States and Latin America, enabling coordinated care that enhances patient engagement and decision-making. Incorporated in 2013 and headquartered in New York, Pager was previously known as techCare, Inc. before rebranding in 2014.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2004. The company specializes in the development of red blood cell-based therapeutics aimed at treating cancer and orphan diseases. Its lead product candidate, eryaspase, is currently undergoing Phase III clinical trials for second-line pancreatic cancer and Phase II trials for triple-negative breast cancer. Additionally, ERYTECH is developing erymethionase, a preclinical candidate targeting methionine-dependent cancers, which consists of methionine-gamma-lyase encapsulated in red blood cells. The company collaborates with research institutions such as the Fox Chase Cancer Center and Queen’s University of Canada to enhance the preclinical development of its products for conditions like homocystinuria and arginase-1 deficiency, respectively. Through its innovative approach to encapsulating therapeutic molecules, ERYTECH Pharma aims to improve the efficacy and safety of its treatments.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

NeueHealth is a healthcare company dedicated to providing high-quality, coordinated care to aging and underserved populations. It operates through two segments: NeueCare, which manages risk in partnership with external payors, serving diverse patient populations; and NeueSolutions, offering technology, services, and clinical care solutions to empower providers.

Upskill designs and develops augmented reality software for industrial workforces. Its flagship platform, Skylight, enables companies to create smart glasses applications for various business scenarios, transforming operations using wearable devices. Serving industries such as manufacturing, healthcare, retail, and logistics, Upskill improves productivity, reduces errors, and enhances training.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

SetPoint Medical Corporation is a clinical-stage medical device company developing implantable neuromodulation therapies to treat chronic inflammatory and autoimmune diseases. Its platform uses vagus nerve stimulation to activate the body's inflammatory reflex, aiming to produce a systemic immune-restorative effect and offer an alternative to drug therapy for conditions such as rheumatoid arthritis and inflammatory bowel disease. Based in Valencia, California.

Evenly is a technology company that enables dentists to offer advanced orthodontic treatments within their practices. Founded in 2019 and headquartered in Washington D.C., the company uses AI technology and 3D printing to provide accurate, remote orthodontic treatment managed by an expert clinical team.

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat diseases like nonalcoholic steatohepatitis (NASH) and certain cancers. The company specializes in targeting dysfunctional metabolic pathways, with a particular expertise in fatty acid synthase (FASN) biology.

Magenta Medical is a private medical device company based in Kadima, Israel, founded in 2012. It develops catheter-based therapies for acute decompensated heart failure, including a self-expanding heart pump and temporary venous catheter-based treatments designed to relieve renal venous congestion. The technology enables quicker and safer removal of excess fluid and salt while protecting renal function, addressing a core pathophysiological element of acute heart failure and related conditions.

Heap Inc. is a company that develops an analytics infrastructure designed for online businesses, enabling them to capture and analyze customer interactions across web, mobile, and cloud platforms. Founded in 2012 and headquartered in San Francisco, California, Heap's solution automates the collection and organization of customer behavioral data, such as clicks, transactions, and form submissions, without requiring additional coding. This streamlined approach allows businesses to gain a comprehensive understanding of their users, facilitating informed decision-making and enhancing product development. Heap serves a diverse range of industries, including e-commerce, financial services, and SaaS, with over 6,000 clients that include notable companies across various sectors. The company is committed to empowering organizations to focus on insights and actions that drive business success.

Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

Collective Health provides a cloud-based health benefits platform that unifies medical, dental, vision, pharmacy, and related programs into a single administration experience, helping employers simplify benefits, guide employees in understanding and navigating care, and manage costs and outcomes. The platform offers integrated administration of all health plans through one portal, with live concierge support and digital tools to find and manage care, and connects employees with medical, pharmacy, dental, and vision providers. Headquartered in San Francisco with offices in Chicago and Lehi, it aims to reduce the administrative burden of delivering benefits while improving member experience and overall health outcomes.

CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.

Intact Vascular, Inc. is a medical device company based in Wayne, Pennsylvania, specializing in the development of minimally invasive products for peripheral vascular procedures. Founded in 2011, the company is known for its Tack Endovascular System, which aims to enhance the results of peripheral balloon angioplasty in treating peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular focuses on creating safe and effective solutions that improve clinical outcomes and quality of life for patients with vascular diseases, while also providing physicians with innovative treatment options.

Vesper Medical, Inc. is a medical device company based in Wayne, Pennsylvania, founded in 2016. The company specializes in the development of minimally invasive peripheral vascular products aimed at treating patients with deep venous disease. Its primary offering is the Vesper DUO Venous Stent System, designed specifically for venous stenting. This system features a unique combination of strength and flexibility to address the complex anatomical challenges encountered in the iliac and femoral veins. Vesper Medical is dedicated to creating safe, effective, and user-friendly products that enhance patient care and support healthcare providers in improving patient outcomes in venous treatment.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Spyglass Ophthalmics, Inc. is a company based in Mission Viejo, California, specializing in the development of ophthalmic therapeutic devices. Founded in 2019, Spyglass focuses on creating innovative solutions to enhance vision and eye care for patients. The company's products target unmet needs in areas such as cataract treatment, lens replacement, and other chronic ophthalmic diseases. By providing these devices, Spyglass aims to ensure that patients receive quality eye treatment at an affordable cost.

THE WELL operates a wellness club and spa, offering personalized health plans tailored by doctors and practitioners. It combines Western medicine with Eastern healing practices, providing members with integrative care and customized plans.

Barricaid is a medical device company that specializes in developing therapeutic solutions for patients undergoing back surgery. Their primary product is a bone-anchored implant designed to reduce the incidence of reherniation and reoperation in patients with large annular defects. The implant works by physically blocking the annulus at the post-surgery defect, using a titanium alloy anchor component that secures the device in position within either the caudal or cranial-adjacent vertebral body. This innovative approach aims to improve outcomes for patients who are at high risk of requiring repeated surgeries due to herniation following lumbar discectomy surgery, particularly those suffering from sciatica.

Strive Health, LLC is a company focused on providing comprehensive solutions for chronic kidney disease. Founded in 2018 and based in Denver, Colorado, Strive Health operates dialysis centers and employs advanced predictive analytics to enhance patient care. The company offers a high-touch, technology-enabled clinical model that supports patients throughout their healthcare journey, from primary care engagement to dialysis treatment. By utilizing comparative and predictive data, Strive Health aims to identify at-risk patients and transform the management of kidney disease, promoting earlier intervention and increasing the adoption of home dialysis. This innovative approach not only improves patient outcomes but also seeks to reduce inpatient utilization, ultimately enhancing the overall experience for individuals dealing with chronic kidney conditions.

Cleo Labs, Inc. is a family support platform that offers pregnancy consultancy and parenthood guidance services to working parents. The company provides a range of consultation services, including lactation support, birth preparation, child wellness, and sleep consulting, as well as career coaching and immediate post-birth assistance. Cleo's mobile application connects families with certified care practitioners, facilitating their journey from fertility through parenting children up to age five. By partnering with employers, Cleo aims to enhance workplace culture, improve employee retention, and foster diverse and inclusive environments. The company operates globally, serving clients in over 50 countries and has collaborated with notable organizations such as eBay and LinkedIn. Founded in 2016 and headquartered in San Francisco, Cleo was previously known as Instacare Group, Inc. before rebranding in 2018.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Eargo, Inc. is a consumer-focused medical device company specializing in the design and sale of hearing aids for individuals with hearing loss in the United States. Founded in 2010 and headquartered in San Jose, California, Eargo offers innovative, rechargeable hearing aids that can be controlled via smartphone, enhancing user convenience. The company provides online hearing screenings and virtual support, eliminating the need for in-person consultations. By adopting a direct-to-consumer model, Eargo aims to make hearing aids more accessible and reduce the social stigma often associated with them. Its user-centric approach addresses the common challenges of traditional hearing aid adoption, including cost and accessibility, thereby improving the quality of life for those with hearing difficulties.

Aetion is a New York‑based company that builds a real‑world evidence platform. It aggregates claims, electronic health records, registries and clinical trial data to generate analytics that help payers, providers, biopharma and medical device firms assess the effectiveness and value of treatments. The platform’s rapid‑cycle analytics enable real‑time collaboration between payers, providers and life‑science companies, supporting value‑based care decisions. Founded in 2012 by Harvard Medical School faculty and data scientists, it has partnerships with McKesson and receives backing from major venture investors. The platform is used worldwide by health‑economists, epidemiologists and biostatisticians for database analytics and comparative‑effectiveness research.